Lexicon Pharmaceuticals Advances Multiple Late-Stage Programs with Key 2026-2027 Milestones
核心洞察
Lexicon's SONATA-HCM Phase 3 trial evaluating sotagliflozin for hypertrophic cardiomyopathy (搜索) is targeting enrollment completion in mid-2026 with topline results expected in Q1 2027.
The company remains on track for Zynquista NDA resubmission in 2026 based on FDA feedback and additional clinical data from the STENO1 study.
Lexicon triggered a $10 million milestone payment from Novo Nordisk for LX9851, an oral ACSL5 (搜索) inhibitor for obesity (搜索), with potential for up to $950 million in remaining milestones.
Lexicon Pharmaceuticals announced significant progress across its clinical pipeline at the 44th Annual J.P. Morgan Healthcare Conference, highlighting multiple potential catalysts expected to drive value through 2027. The company's strategic focus on cardiometabolic diseases positions it to address critical unmet medical needs with breakthrough therapies.
"As we look ahead to 2026, Lexicon stands at the threshold of multiple potential catalysts demonstrating the strength of our pipeline and our cardiometabolic expertise," said Mike Exton, Ph.D., Lexicon's chief executive officer and director. "We have pioneered entirely new classes of investigative treatments for critical unmet medical needs, and advanced them into late-stage development."
Sotagliflozin Advances in Hypertrophic Cardiomyopathy
The SONATA-HCM pivotal Phase 3 study evaluating sotagliflozin in hypertrophic cardiomyopathy (搜索) (HCM) remains on track for key milestones. The study is targeting enrollment of 500 patients with both obstructive and non-obstructive HCM, with anticipated enrollment completion in mid-2026. Topline results are anticipated in Q1 2027.
This represents a significant advancement for patients with HCM, a condition where limited treatment options exist. The successful completion of this trial could establish sotagliflozin as a new therapeutic option for this patient population.
Zynquista Regulatory Path Forward
Lexicon remains on track for New Drug Application (NDA) resubmission in 2026 for Zynquista (sotagliflozin) in Type 1 diabetes (搜索), based on FDA feedback and additional clinical data from the STENO1 study. The FDA provided feedback that the STENO1 study appears to be of adequate design and employs sufficient data collection methods to provide viable evidence of the incidence of diabetic ketoacidosis (搜索) (DKA) with adequate safety data to support review of a resubmission.
Based on current STENO1 enrollment estimates, regulatory feedback from the FDA supports a potential NDA resubmission and regulatory approval in 2026, if the patient exposure and safety data requirements identified by the FDA for STENO1 are achieved. STENO1 is a third-party funded, investigator-initiated study of sotagliflozin being conducted by the Steno Diabetes Center in Denmark.
Strategic Partnership Milestones
Lexicon's partnership with Novo Nordisk for LX9851, an oral ACSL5 (搜索) inhibitor for obesity (搜索), reached a significant milestone with a $10 million payment triggered in January. The company has received $45 million from Novo Nordisk to date, with up to $950 million in remaining potential milestones plus tiered royalties on net sales. Additional milestone payments of up to $20 million are possible in 2026.
IND-enabling activities for LX9851 have been completed by Lexicon, positioning the program for clinical advancement under Novo Nordisk's development leadership.
Expanding Non-Opioid Pain Treatment Options
Lexicon and the FDA held a productive End-of-Phase 2 meeting in the fourth quarter of 2025 for pilavapadin in neuropathic pain (搜索). The company continues to advance partnership discussions to maximize the global potential of this investigative therapy. Significant unmet need exists for new, non-opioid alternatives to pain therapy with various efforts underway to prioritize new methods of pain relief, including the potential introduction of supportive legislation.
International Commercial Expansion
The sotagliflozin program continues its international expansion through Viatris, with regulatory approval received in the United Arab Emirates (UAE) and commercial supply provided by Lexicon. Regulatory applications were submitted in several other markets including Canada, Australia and New Zealand in 2025, with additional regulatory submissions and approvals expected throughout 2026 in key international markets.
Financial Position and Operational Efficiency
Lexicon ended 2025 with cash, investments and restricted cash of $125.2 million (unaudited), sufficient to support planned operations into 2027. Scott Coiante, Lexicon's senior vice president and chief financial officer, noted that the company's efforts in 2025 to reduce operating expenses and become increasingly efficient in operations contributed to this strong cash position.
The cash runway excludes the impact of milestone payments related to LX9851 and other non-dilutive capital opportunities related to pilavapadin, providing additional financial flexibility for the company's development programs.